Episode 15: The Latest Developments in the SMA Treatment Landscape


"Mind Moments," a podcast from NeurologyLive, brings you an exclusive interview with Richard Finkel, MD.

Dr Richard Finkel

Jeffrey Cummings, MD, ScD, director emeritus, Lou Ruvo Center for Brain Health, Cleveland Clinic, and vice-chair, Department of Brain Health, University of Nevada Las Vegas

Richard Finkel, MD

Episode 15 of the NeurologyLive Mind Moments podcast is now live! Scroll down to listen or click here to subscribe on your favorite streaming service.

The Mind Moments podcast features exclusive interviews with leaders in the field discussing the latest research and disease management strategies across the breadth of neurology, including epilepsy, multiple sclerosis, Parkinson disease, dementia, sleep disorders, and more.

Episode 15, "A New Approval: The SMA Treatment Landscape," features an interview with Richard Finkel, MD, pediatric neurologist, and head, Center for Experimental Neurotherapeutics, St. Jude Children’s Research Hospital. Finkel offered an in-depth look at how the recent FDA approval of oral risdiplam (Evrysdi; Roche) might impact the spinal muscular atrophy (SMA) therapeutic landscape.

Click here to subscribe to the Mind Moments podcast. Thanks for listening!

Related Videos
Sanjay R. Patel, MD, MS
Patricia K. Coyle, MD
Video 2 - 5 KOLs are featured in "Natural History of Spinal Muscular Atrophy"
Video 1 - 5 KOLs are featured in "Clinical Features and Phenotypes of Spinal Muscular Atrophy"
Aliza Ben-Zacharia, PhD, DNP, ANP-BC, FAAN
© 2024 MJH Life Sciences

All rights reserved.